5 results on '"Antonio Canosa"'
Search Results
2. A patient with demyelinating CMT carrying the p.Y347C heterozygous variant of the MME gene and the p.L131F heterozygous variant of the HARS1 gene
- Author
-
Mattia Parisi, Antonio Canosa, Alessandra Tessa, Bruno Ferrero, and Salvatore Gallone
- Subjects
Psychiatry and Mental health ,Neurology (clinical) ,Dermatology ,General Medicine - Published
- 2022
3. Brain metabolic changes across King's stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography study
- Author
-
Vincenzo Arena, Philip Van Damme, Adriano Chiò, Marco Pagani, Davide Nardo, Koen Van Laere, Umberto Manera, Antonio Canosa, Rosario Vasta, Andrea Calvo, Sara Cabras, Fabrizio D'Ovidio, Francesca Di Pede, Cristina Moglia, Maurizio Grassano, Canosa, Antonio [0000-0001-5876-4079], Apollo - University of Cambridge Repository, Canosa, Antonio, Calvo, Andrea, Moglia, Cristina, Manera, Umberto, Vasta, Rosario, Di Pede, Francesca, Cabras, Sara, Nardo, Davide, Arena, Vincenzo, Grassano, Maurizio, D'Ovidio, Fabrizio, Van Laere, Koen, Van Damme, Philip, Pagani, Marco, and Chiò, Adriano
- Subjects
King's staging system ,education ,030218 nuclear medicine & medical imaging ,18F-FDG-PET ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Fluorodeoxyglucose F18 ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Amyotrophic lateral sclerosis ,Stage (cooking) ,Amyotrophic lateral sclerosi ,Science & Technology ,medicine.diagnostic_test ,ABNORMALITIES ,business.industry ,Radiology, Nuclear Medicine & Medical Imaging ,Neurodegeneration ,Amyotrophic Lateral Sclerosis ,Brain ,General Medicine ,Anatomy ,Medial frontal gyrus ,medicine.disease ,F-FDG-PET ,King’s staging system ,medicine.anatomical_structure ,Glucose ,chemistry ,Positron emission tomography ,F-18-FDG-PET ,Positron-Emission Tomography ,Original Article ,Body region ,2-Deoxy-D-glucose ,business ,Life Sciences & Biomedicine ,030217 neurology & neurosurgery ,Motor cortex ,Human - Abstract
Purpose To assess the brain metabolic correlates of the different regional extent of ALS, evaluated with the King’s staging system, using brain 18F-2-fluoro-2-deoxy-d-glucose-PET (18F-FDG-PET). Methods Three hundred ninety ALS cases with King’s stages 1, 2, and 3 (n = 390), i.e., involvement of 1, 2, and 3 body regions respectively, underwent brain 18F-FDG-PET at diagnosis. King’s stage at PET was derived from ALSFRS-R and was regressed out against whole-brain metabolism in the whole sample. The full factorial design confirmed the hypothesis that differences among groups (King’s 1, King’s 2, King’s 3, and 40 healthy controls (HC)) existed overall. Comparisons among stages and between each group and HC were performed. We included age at PET and sex as covariates. Results Brain metabolism was inversely correlated with stage in medial frontal gyrus bilaterally, and right precentral and postcentral gyri. The full factorial design resulted in a significant main effect of groups. There was no significant difference between stages 1 and 2. Comparing stage 3 to stage 1+2, a significant relative hypometabolism was highlighted in the former in the left precentral and medial frontal gyri, and in the right medial frontal, postcentral, precentral, and middle frontal gyri. The comparisons between each group and HC showed the extension of frontal metabolic changes from stage 1 to stage 3, with the larger metabolic gap between stages 2 and 3. Conclusions Our findings support the hypothesis that in ALS, the propagation of neurodegeneration follows a corticofugal, regional ordered pattern, extending from the motor cortex to posterior and anterior regions.
- Published
- 2021
4. Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis
- Author
-
Leonardo Iaccarino, Caterina Pagnini, Adriano Chiò, Piercarlo Fania, Antonio Canosa, Emilia Giovanna Vanoli, Federico Fallanca, Chiara Cerami, Andrea Calvo, Arianna Sala, Daniela Perani, Marco Pagani, Angelina Cistaro, Sala, Arianna, Iaccarino, Leonardo, Fania, Piercarlo, Vanoli, Emilia G., Fallanca, Federico, Pagnini, Caterina, Cerami, Chiara, Calvo, Andrea, Canosa, Antonio, Pagani, Marco, Chiò, Adriano, Cistaro, Angelina, and Perani, Daniela
- Subjects
Male ,Nervous system ,Radiology, Nuclear Medicine and Imaging ,Pathology ,medicine.medical_specialty ,Cerebellum ,[18F]FDG-PET ,Central nervous system ,Sensitivity and Specificity ,030218 nuclear medicine & medical imaging ,Diagnosis, Differential ,Brain metabolism ,03 medical and health sciences ,0302 clinical medicine ,Fluorodeoxyglucose F18 ,Cortex (anatomy) ,Diagnosis ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Amyotrophic lateral sclerosis ,Biomarkers ,Amyotrophic lateral sclerosi ,Fluorodeoxyglucose ,Medulla Oblongata ,Motor Cortex ,Biomarker ,General Medicine ,Middle Aged ,Spinal cord ,medicine.disease ,Spine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,Primary motor cortex ,Diagnosi ,medicine.drug - Abstract
Purpose: The role for [18F]FDG-PET in supporting amyotrophic lateral sclerosis (ALS) diagnosis is not fully established. In this study, we aim at evaluating [18F]FDG-PET hypo- and hyper-metabolism patterns in spinal- and bulbar-onset ALS cases, at the single-subject level, testing the diagnostic value in discriminating the two conditions, and the correlations with core clinical symptoms severity. Methods: We included 95 probable-ALS patients with [18F]FDG-PET scan and clinical follow-up. [18F]FDG-PET images were analyzed with an optimized voxel-based-SPM method. The resulting single-subject SPM-t maps were used to: (a) assess brain regional hypo- and hyper-metabolism; (b) evaluate the accuracy of regional hypo- and hyper metabolism in discriminating spinal vs. bulbar-onset ALS; (c) perform correlation analysis with motor symptoms severity, as measured by ALS-FRS-R. Results: Primary motor cortex showed the most frequent hypo-metabolism in both spinal-onset (∼57%) and bulbar-onset (∼64%) ALS; hyper-metabolism was prevalent in the cerebellum in both spinal-onset (∼56.5%) and bulbar-onset (∼55.7%) ALS, and in the occipital cortex in bulbar-onset (∼62.5%) ALS. Regional hypo- and hyper-metabolism yielded a very low accuracy (AUC
- Published
- 2019
5. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients
- Author
-
Maura Brunetti, Angelina Cistaro, Cristina Moglia, Anna Montuschi, Leonardo Lopiano, Gabriella Restagno, Andrea Calvo, M. Consuelo Valentini, Piercarlo Fania, Bryan J. Traynor, Marco Pagani, Antonio Canosa, Giovanna Carrara, Adriano Chiò, and Flavio Nobili
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Gene mutation ,Article ,Fluorodeoxyglucose F18 ,C9orf72 ,Nuclear Medicine and Imaging ,C9ORF72 gene ,Amyotrophic lateral sclerosis, C9ORF72 gene, FDG PET ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Amyotrophic lateral sclerosis ,Aged ,Cerebral Cortex ,Fluorodeoxyglucose ,C9orf72 Protein ,medicine.diagnostic_test ,Medicine (all) ,Case-control study ,Proteins ,General Medicine ,Middle Aged ,medicine.disease ,FDG PET ,Amyotrophic Lateral Sclerosis ,Case-Control Studies ,Female ,Mutation ,Positron-Emission Tomography ,Radiopharmaceuticals ,Radiology, Nuclear Medicine and Imaging ,Positron emission tomography ,Radiology ,Trinucleotide repeat expansion ,medicine.drug - Abstract
PURPOSE: Recently, a GGGGCC hexanucleotide repeat expansion in the C9ORF72 gene, located on chromosome 9p21 has been demonstrated to be the commonest cause of familial amyotrophic lateral sclerosis (ALS) and to account for 5 to 10 % of apparently sporadic ALS. Relatively little is known about the brain metabolism profile of patients carrying the expansion. Our aim was to identify the [18F]FDG PET profile in ALS patients with the C9ORF72 expansion (C9ORF72-ALS). METHODS: Fifteen C9ORF72-ALS patients were compared with 12 patients with ALS and comorbid frontotemporal dementia (FTD) without the C9ORF72 expansion (ALS-FTD) and 30 cognitively normal patients with ALS without mutations of ALS-related genes (sALS). The three groups were then cross-matched to 40 neurologically normal controls. All patients underwent FDG PET within 4 months of diagnosis. RESULTS: The C9ORF72-ALS patients compared with the sALS patients showed significant hypometabolism in the anterior and posterior cingulate cortex, insula, caudate and thalamus, the left frontal and superior temporal cortex, and hypermetabolism in the midbrain, bilateral occipital cortex, globus pallidus and left inferior temporal cortex. The ALS-FTD patients compared with the sALS patients showed more limited hypometabolic areas, including the orbitofrontal, prefrontal, anterior cingulate and insular cortex, and hypermetabolic areas, including the bilateral occipital cortex, the left precentral and postcentral cortex and superior temporal gyrus. The C9ORF72-ALS patients compared with the ALS-FTD patients showed hypometabolism in the left temporal cortex. CONCLUSION: ALS patients with the C9ORF72 hexanucleotide repeat expansion had a more widespread central nervous system involvement than ALS patients without genetic mutations, with or without comorbid FTD, consistent with their more severe clinical picture.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.